MPIMalaysian Pharmaceutical
Intelligence
BETALook up
Fields · C10

Lipid-lowering

Statins and a fibrate. The class is almost entirely off-patent and multi-sourced; value sits in the high-intensity statins.

38.1%
Prevalence
8,700,000
Estimated patients
30%
On treatment
RM 0.3–1.8B
Market / yr*
Burden: NHMS 2019 (2019) · * Coarse open estimate — NHMS 2019 treated patients × MOH published therapy cost (~1 DDD/day). Order-of-magnitude; precise molecule-level size & market concentration are in the read.
Market structure, at a glance.
The 7 tracked molecules in this field, grouped by makers and patent status. A neutral count — no verdict.
2 generic-open
4 multi-source
1 not yet registered
Generic-open — off-patent, generics registeredMulti-source — 10+ registered makersNot yet registered — no NPRA footprint on file
Generic-open2 molecules
Lovastatin
3 registered maker(s) · off-patent, generics registered · statin
Pravastatin
3 registered maker(s) · off-patent, generics registered · statin
Multi-source4 molecules
Rosuvastatin
29 registered makers · market already open · statin
Atorvastatin
19 registered makers · market already open · statin
Simvastatin
17 registered makers · market already open · statin
Fenofibrate
10 registered makers · market already open · fibrate
Not yet registered1 molecule
Fluvastatin
no registered maker and no patent on file · statin